Seattle-based Company Aiberry Raised $8M Seed Funding to Accelerate AI-Powered Mental Health Screenings



Aiberry, the pioneer in AI-powered mental health screening, announced today that it has raised $8 million in seed funding led by Confluence Capital Group, with participation from the VC fund Ascension AI. The new funds will be used to accelerate adoption of the Aiberry platform, which uses an AI-powered therapeutic assistant to conduct a conversation to detect mental health disorders by analyzing what is said, speech patterns used, and even subtle changes in facial expressions.

“Our investment thesis is to apply artificial intelligence to solve practical problems in healthcare so that it drastically improves outcomes,” said Stewart Williams, partner at Confluence Capital Group.

“Healthcare leader Linda Chung and veteran technology leader Johan Bjorklund, co-founders and co-CEOs are uniquely suited to drive this innovation,” said Wade Brooks, fund manager of Ascension AI.

“AI platforms such as Aiberry provide a wide range of benefits compared to traditional diagnostic methods,” said Lynne Dunbrack, Group Vice President for IDC Health Insights. “They eliminate the tedious process of filling out lengthy intake forms that fail to provide a comprehensive understanding of the patient’s situation. Furthermore, these platforms offer objective progress tracking, reducing the impact of human bias and increasing the reliability and accuracy of results.”

Aiberry’s platform enables screenings in a variety of settings, including doctor’s offices, schools, workplaces, and even homes. Its AI-powered therapeutic assistant has a gentle voice and inviting demeanor that puts users at ease, and it is available 24 hours a day, seven days a week. Users and clinicians are given a risk level score for mental health disorders, including suicidal ideation, at the end of each screening, as well as screening insights such as mood, concentration, and energy levels. Dr. Newton Howard, a leading brain and cognitive scientist and professor at Georgetown University and Oxford University, who is also a co-founder and Chief Scientist at Aiberry, is the inspiration for Aiberry.

Clinicians, corporate wellness providers, and other mental health professionals considering telehealth, text-based therapy, and on-demand content frequently base their decisions on user numbers, which do not provide a clear indication of their impact. Aiberry’s platform provides quantifiable and objective results that can be tracked over time to provide a more reliable measure of success. This makes it simple for organizations to determine which mental health resource is the best investment for their specific needs and goals.

Aiberry (pronounced “I” + “berry”) is an innovative and practical mental health screening solution that improves efficiency and saves time for healthcare providers. Its cutting-edge AI technology is based on two decades of research bundled into a powerful solution that helps providers better serve their patients. Its Machine Learning (ML) pipelines are designed to eliminate biases, including those related to age, gender, sexual orientation and race. Seattle-based Aiberry is backed by leading VCs including Confluence Capital Group, Inc. (CCG) and Ascension AI.

Related Stories